S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study

Abstract

Background and Objectives S-1-based regimens have been shown to be as effective as other fluoropyrimidine-based regimens with a better safety profile in patients with advanced esophagogastric adenocarcinoma. However, real-world data on S-1 in European patients with advanced esophagogastric adenocarcinoma are lacking. The Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) study evaluated safety and relative dose intensities for patients treated with S-1-based regimens for advanced esophagogastric adenocarcinoma as part of daily practice. Methods Overall, data for 125 patients with advanced esophagogastric adenocarcinoma were collected at 21 centers in five countries in Europe. Demographics, treatment, and adverse-event data were recorded over a planned treatment of six cycles. Results Most patients (87%) received combination treatment of S-1 plus a platinum compound. Adverse events related to S-1 treatment were mostly grade 1 or 2 while reported grade 3–4 serious adverse events related to S-1 occurred in 12 patients and were most often grade 3 neutropenia ( n = 4, 3.2%) or diarrhea ( n = 5, 4%). The most common adverse events of any grade that were attributable to S-1 treatment included neutropenia, anemia, thrombocytopenia, diarrhea, nausea, vomiting, and fatigue. No patients experienced mucositis, dehydration, or febrile neutropenia, whereas 2% (3/125) of patients experienced hand-foot syndrome. Conclusion The overall relative dose intensity was 70%. In a real-world setting, patients with advanced esophagogastric adenocarcinoma tolerated S-1 treatment well with high compliance rates. The SCOOP study provides valuable information on S-1 relative dose intensity that can be used for treatment decision making.

Review: Prevention and management of gastric cancer

“…No new treatment emerged for patients with advanced non‐resectable GC in the last year (Table 1). 8,9 …”

Review: Gastric cancer—Clinical aspects

“…In the First‐Line Advanced Gastric Cancer Study (FLAGS), the combination of S‐1 with cisplatin was non‐inferior to infusional fluorouracil with cisplatin in OS for patients with advanced GC/EGJ cancer and resulted in a significantly improved safety profile. In the phase IV Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) study conducted at 21 centers in five European countries, the relative dose intensity for S‐1 treatment was 69.8%, with a very favorable safety profile . These real‐world data on treatment compliance and adverse events are of value to physicians when choosing between available options for the treatment of patients with advanced GC/EGJ cancer.…”